Gastroenterology-focused pharmaceutical company Phantom Pharmaceuticals will appoint Terrie Curran as CEO after Celgene Corp. is acquired by Bristol-Myers Squibb.
What you should know:
1. Ms. Curran will succeed David Socks.
2. Mr. Socks will serve as CEO through the acquisition and will then transition into an interim CFO role. He'll continue to serve on Phantom's board.
3. Ms. Curran comes to the company from Celgene Corp., where she was president of the global inflammation and immunology franchise, and served as a member of the executive committee.
4. Phantom concurrently made three appointments to its board: Michael Cola, Heidi Kunz and Chris Slavinsky.